BALPHARMA vs DRREDDY: Stock Comparison

Bal Pharma Limited vs Dr Reddys Laboratories Ltd

Live data: 22 July 2026, 2:53 PM IST • Source: NSE and company filings

Dr Reddys Laboratories Ltd is the larger company by market capitalisation. Bal Pharma Limited shows a higher dividend yield and faster revenue growth, while Dr Reddys Laboratories Ltd shows a higher ROE, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Bal Pharma Limited and Dr Reddys Laboratories Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BALPHARMA is more favourable on 5 of 11 scored metrics and DRREDDY on 6These counts are context-free and are not an overall rating.

Key Differences

Market Cap
DRREDDY is the larger company
₹98,815 Cr vs ₹139 Cr
EPS
DRREDDY has higher earnings per share
₹51.37 vs ₹3.95
Dividend Yield
BALPHARMA has a higher dividend yield
1.32% vs 0.65%
Revenue Growth (TTM YoY)
BALPHARMA has faster revenue growth
2.7% vs -11.6%
EPS Growth (TTM YoY)
BALPHARMA has faster EPS growth
-33.5% vs -86.2%
Qtr Sales Growth
BALPHARMA has stronger quarterly sales growth
2.69% vs -11.5%
Qtr Profit Growth
BALPHARMA has stronger quarterly profit growth
-33.9% vs -86.1%
ROE
DRREDDY has a higher ROE
11.2% vs 7.87%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBALPHARMADRREDDY
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBALPHARMADRREDDY
Live Price₹87.77₹1,182.2
Day Change-1.67%-1.97%
Volume16,92420.44 L
52-Week High₹102.99₹1,414.9
52-Week Low₹60₹1,148.4
Distance from 52W High-14.78%-16.45%

Valuation

MetricBALPHARMADRREDDY
Market Cap₹139 Cr₹98,815 Cr
P/E Ratio24x
P/B Ratio2.66x
EPS₹3.95₹51.37
Book Value₹51.71₹452.82
Dividend Yield1.32%0.65%

Growth

MetricBALPHARMADRREDDY
Revenue Growth (TTM YoY)2.7%-11.6%
EPS Growth (TTM YoY)-33.5%-86.2%
Qtr Sales Growth2.69%-11.5%
Qtr Profit Growth-33.9%-86.1%

Profitability & Leverage

MetricBALPHARMADRREDDY
ROE7.87%11.2%
ROCE9.69%13%
Net Margin2.02%12.76%
Operating Margin10.2%19.2%
Debt to Equity1.94x0.2x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBALPHARMADRREDDY
Promoter Holding46.74%26.63% 0.01 pp
FII Holding0.15% 0.01 pp33.08% 0.12 pp
DII Holding0%30.72% 0.28 pp
Public Holding48.99% 0.02 pp9.33% 0.14 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Bal Pharma Limited and Dr Reddys Laboratories Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.